Background. Sentinel lymph node biopsy (SLNB) is widely used in melanoma. Identifying nodal involvement preoperatively by high-resolution ultrasound may offer less invasive staging. This study assessed feasibility and staging results of clinically targeted ultrasound (before lymphoscintigraphy) compared to SLNB. Methods. From 2005 to 2009, a total of 325 patients with melanoma underwent ultrasound before SLNB. We reviewed demographics and histopathologic characteristics, then compared ultrasound and SLNB results. Sensitivity, specificity, and positive and negative predictive value were determined. Results. A total of 325 patients were included, 58% men and 42% women with a median age of 58 (range 18-86) years. A total of 471 basins were examined with ultrasound. Only six patients (1.8%) avoided SLNB by undergoing ultrasound-guided fine-needle aspiration of involved nodes, then therapeutic lymphadenectomy. Sixtyfive patients (20.4%) had 69 SLNB positive nodal basins; 17 nodal basins from 15 patients with positive ultrasounds were considered truly positive. Forty-five SLNB positive basins had negative ultrasounds (falsely negative). Seven node-positive basins did not undergo ultrasound because of unpredicted drainage. A total of 253 patients with negative SLNBs had negative ultrasounds in 240 nodal basins (truly negative) but falsely positive ultrasounds occurred in 40 basins. Overall, sensitivity of ultrasound was 33.8%, specificity 85.7%, positive predictive value 36.5%, and negative predictive value 84.2%. Sensitivity and specificity improved somewhat with increasing Breslow depth. Sensitivity was highest for the neck, but specificity was highest for the groin.
SLNBs had negative ultrasounds in 240 nodal basins (truly negative) but falsely positive ultrasounds occurred in 40 basins. Overall, sensitivity of ultrasound was 33.8%, specificity 85.7%, positive predictive value 36.5%, and negative predictive value 84.2%. Sensitivity and specificity improved somewhat with increasing Breslow depth. Sensitivity was highest for the neck, but specificity was highest for the groin. Conclusions. Routine preoperative ultrasound in clinically node-negative melanoma is impractical because of its low sensitivity. Selected patients with thick or ulcerated lesions may benefit. Because of variable lymphatic drainage patterns, preoperative ultrasound without lymphoscintigraphic localization will provide incomplete evaluation in many cases.
Nodal status is an important prognostic indicator in melanoma patients and guides optimal treatment methods.
1,2 Sentinel lymph node biopsy (SLNB) has been accepted as a preferred method for initial lymph node staging of patients with clinically node-negative melanoma. [3] [4] [5] However, it is still invasive, associated with definite morbidity, and usually performed under general anesthesia. Furthermore, only 15-30% of clinically nodenegative melanoma patients will have a positive SLNB, and a delay before undergoing therapeutic lymphadenectomy is usually experienced by those patients while waiting for the final pathology result. 2, 6 Thus, detecting nodal involvement by preoperative ultrasound appears to be an attractive option to eliminate the need for SLNB and its potential complications, and minimize costs of lymphoscintigraphy and the delay to therapeutic lymphadenectomy for node-positive patients.
High-resolution ultrasound has been shown to be useful in follow-up evaluation of nodal basins postoperatively. [7] [8] [9] [10] [11] [12] However, the role of preoperative ultrasound in the initial staging of cutaneous melanoma patients is unclear. [13] [14] [15] [16] [17] [18] Studies have suggested that ultrasound-guided fine-needle aspiration (FNA) of suspicious lymph nodes may accurately detect nodal metastasis, enabling one-stage lymphadenectomy of affected nodal basins. 16, 17 The purpose of our study was to assess feasibility of preoperative nodal ultrasound without lymphoscintigraphy localization of draining nodal basins as a screening tool in melanoma patients before SLNB. The secondary purpose was to compare the sensitivity and specificity of preoperative ultrasound in the detection of nodal metastasis when compared to SLNB.
PATIENTS AND METHODS

Patient Selection
After institutional review board approval, the ultrasound database at our institution was queried for nodal ultrasounds performed on cutaneous melanoma patients. A total of 405 melanoma patients had nodal ultrasounds between June 2005 and September 2009. Of these patients, 325 patients met the inclusion criteria, which were the following: confirmed diagnosis of primary cutaneous melanoma without palpable lymphadenopathy in regional nodal basins; ultrasound performed before scheduled lymphoscintigraphy and SLNB; and no clinical evidence of distant metastasis.
Clinical Targeting of Nodal Basins
The nodal ultrasound was ordered according to the primary melanoma site and at the discretion of the attending surgeon; it was intended to encompass all basins potentially draining the primary site. Patients with extremity melanomas underwent ultrasound of the ipsilateral groin or axilla. Generally, patients with melanoma on the hand or forearm also had an epitrochlear ultrasound, while patients with melanoma on the lower leg, from toe to calf, had a popliteal ultrasound. Head and neck melanomas underwent, at minimum, ipsilateral neck, parotid, and supraclavicular ultrasound. For melanomas on the trunk, Sappey's line was used as a rough guide: melanomas at or above the beltline included axillary ultrasound, and those at or below included groin ultrasound. Lesions in close proximity to the midline had bilateral ultrasounds performed.
Nodal Ultrasound
The preoperative ultrasound was performed with highresolution linear 9 and 12 MHz transducers either immediately or several days before lymphoscintigraphy. No absolute criteria were used for evaluating nodes ultrasonographically, but in general, suspicious lymph nodes appeared round in shape, had partial or complete absence of the fatty hilum, and/or had diffuse or eccentric thickening of the cortex. 10, 14, 19 The loss of central perfusion or presence of peripheral perfusion was not included in the morphologic criteria. 20 The size of the lymph node by itself was not considered an indication of abnormality. 13 For correlation with SLNB results, readings of ''benign'' or ''no nodes visualized'' were considered negative, and readings called ''abnormal,'' ''suspicious,'' or ''indeterminate recommending a short-term follow-up'' were scored as positive. In cases of an abnormal ultrasound performed before the day of surgery, patients were offered an ultrasound-guided FNA and, if positive, proceeded directly to therapeutic lymphadenectomy without SLNB; patients with a negative FNA underwent SLNB.
Sentinel Lymph Node Biopsy
SLNB was offered to medically fit patients with melanoma depth C0.76 mm without palpable lymphadenopathy or \0.76 mm with high-risk features such as ulceration, high mitotic rate, or a positive deep margin. 21, 22 Lymphoscintigraphy was performed the morning of surgery by injecting radiolabeled colloid (either 99m Tc-sulfur colloid or 99m Tc-tilmanocept) 23 at the primary tumor site. In the operating room, 1-2 ml of isosulfan blue dye was injected intradermally. Sentinel lymph nodes were identified on the basis of blue color, radioactivity above background and at least 10% of the hottest node, or palpable abnormality. All sentinel nodes were serially sectioned and evaluated by hematoxylin-eosin and immunohistochemical staining. All lymph nodes with proven tumor deposits, regardless of size, were considered positive.
Ultrasound and Sentinel Lymph Node
By the nature of our study, we were unable to determine whether a pathologically involved node was in fact visualized and abnormal by ultrasound. To provide a best-case estimate of the accuracy of preoperative ultrasound, whenever the ultrasound was considered abnormal and the SLNB was positive, it was considered to be a truly positive finding. An abnormal ultrasound with a negative SLNB was considered to be falsely positive, and a normal ultrasound with a positive SLNB was considered to be falsely negative. Any nodal basin with a normal ultrasound and negative SLNB was considered truly negative. We calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) with these variables. The evaluation of data was performed with the statistical package SPSS version 18.0.0 (SPSS, Chicago, IL) and standard formulas.
RESULTS
Patient and Tumor Characteristics
A total of 325 patients (58% men, 42% women) with median age of 58 (range 18-86) years at the time of presentation were included in our study ( Table 1 ). The primary melanoma sites, in decreasing order of frequency, were trunk (39.7%), upper extremity (31.1%), lower extremity (18.8%), and head and neck (10.5%). Median tumor depth was 1.78 mm (range 0.42-14.40): 17.2% of patients had a melanoma B1.00 mm; 41.8% between 1.01 and 2.00 mm; 27.1% between 2.01 and 4.00 mm; and 13.5% [4.00 mm. The depth was not measurable in one patient as a result of missing epithelium in the biopsy specimen. Clark's level CIV tumors comprised the majority (90.8%), and ulceration was observed in 29.8%.
Ultrasound-guided Fine-needle Aspiration
In our study, only 10 patients (3.1%) were able to have an ultrasound-guided FNA before SLNB. Of the 10 patients, six had metastases seen on cytology and underwent a therapeutic lymphadenectomy. All six patients had evidence of nodal metastasis in the lymphadenectomy specimen ranging from one to five positive lymph nodes. The median tumor depth for these six patients was 7.04 (3.9-14.0) mm; five of six had a depth [4 mm, and all had ulceration. The four patients who had negative cytology also had a negative SLNB. However, one of the four who had negative FNA and SLNB presented with a nodal metastasis 6 months after SLNB. Systemic and practical issues precluded most of our patients with an abnormal ultrasound from undergoing ultrasound-guided FNA; almost all went on to same-day lymphoscintigraphy and SLNB.
Ultrasound and Lymphoscintigraphy
Excluding the six FNA-positive patients, 319 patients underwent lymphoscintigraphy after ultrasound and before SLNB. A total of 506 nodal basins were evaluated by ultrasound, lymphoscintigraphy, or both. Ultrasound was performed on 471 nodal basins, while the lymphoscintigraphy identified only 374 draining nodal basins. Only 342 basins had both ultrasound and lymphoscintigraphy evaluation: 99 patients had lymphatic basins evaluated by ultrasound but not localized by lymphoscintigraphy, meaning that 31% of patients had a superfluous ultrasound of one or more nondraining basins. Of these 99 patients, 77% had a primary tumor located on the trunk, 15% on shoulder/upper extremity, and 8% on the scalp/neck. Twenty-four patients had the popliteal region evaluated with ultrasound, but in 22 of these patients popliteal nodes were not localized with lymphoscintigraphy. One of the two patients with lymphoscintigraphy localization had a positive popliteal SLNB, and the other had a negative popliteal SLNB. Four patients had ultrasound of an epitrochlear basin not localized with lymphoscintigraphy.
On the other hand, 29 patients (9.1%) had basins localized by lymphoscintigraphy but not evaluated by ultrasound: 24 (83%) had the primary tumor located on the trunk and five (17%) on the shoulder/upper extremity. Eight patients (27.6%) had in-transit nodes not predicted clinically but mapped by lymphoscintigraphy, such as latissimus, inframammary, and scapular regions. Furthermore, seven of 29 patients (24.1%) had positive SLNBs in nodal basins not examined with ultrasound. One patient had ultrasound of a nondraining nodal basin, while the actual draining basin identified by lymphoscintigraphy was not examined with ultrasound; this patient was not included in further analysis for comparison between ultrasound and SLNB.
Ultrasound and SLNB
Of 318 patients with SLNBs, 65 patients (20.4%) had 69 basins with at least one histologically positive sentinel lymph node. Four patients had two positive SLNBs, and as stated above, seven node-positive patients (10.8%) did not have preoperative ultrasound of the positive nodal basin. Seventeen of the 65 node-positive patients (26%) also had an abnormal ultrasound, but only 15 patients had truly positive correspondence between the ultrasound and SLNB, as two patients had two nodal basins localized by lymphoscintigraphy and each contained positive nodes but only one site was identified as positive by ultrasound. In the face of a negative SLNB, 40 nodal basins had an abnormal ultrasound. A total of 253 patients had negative SLNB findings, resulting in 305 negative nodal basins; however, only 279 of those nodal basins had both ultrasound and lymphoscintigraphy localization.
All 10 patients who underwent ultrasound-guided FNA were included in our analysis for the usefulness of preoperative ultrasound. The six patients who underwent onestage therapeutic lymphadenectomy were counted as truly positive. Analysis was performed per patient and per basin. If a patient had multiple nodal basins evaluated and had false-negative finding in one basin, the case was considered to be falsely negative. The sensitivity of preoperative ultrasound, per patient, was 31.8%, and the specificity was 86%. The PPV was 36.8% and the NPV was 83.1%. When these values were analyzed per nodal basin, the results were similar (Table 2 ). In-transit or epitrochlear nodal basins were not included in the analysis because the nodal basins either lack ultrasound evaluation or SLNB result. When the data were analyzed by tumor and anatomic subsets, sensitivity increased with increasing Breslow depth but was still low (45.8%) even for the thick melanomas. The PPV improved with increasing Breslow depth, but the NPV decreased. When comparing by anatomic location of draining nodal basins, the neck had the highest sensitivity at 43.3%, while specificity and PPV were the highest for the groin.
Of 279 nodal basins with negative SLNBs and negative ultrasounds, eight nodal basins required subsequent completion lymphadenectomy (false-negative SLNB). Six nodal basins produced metastatic lymph nodes, but two nodal basins only demonstrated soft tissue metastasis without lymph node involvement. Four of the six basins had a negative ultrasound evaluation preoperatively, and one had indeterminate findings with nonspecific lymph nodes recommending a short-term follow-up. The other nodal basin showed suspicious nodes on ultrasound, leading to a preoperative ultrasound-guided FNA. However, the cytology was negative, and the SLNB was also negative. Unfortunately, the patient presented with nodal metastasis 6 months postoperatively.
DISCUSSION
Although the morbidity of SLNB is much lower than for elective lymph node dissection, it is not negligible. 24 Considering that most patients with thin and intermediatethickness melanomas will have negative SLNBs, pursuit of [25] [26] [27] Imaging modalities such as ultrasound, CT, MRI, and PET have been considered to be better than palpation for detection of nodal metastases. 19, [28] [29] [30] However, when PET/CT was compared to SLNB for detection of occult lymphatic metastasis, SLNB was better for detecting small tumor deposits. 31 Compared to other imaging modalities, ultrasound is less invasive, less expensive, and better tolerated by patients. Preoperative ultrasound may detect abnormal lymph nodes that could not be localized via lymphoscintigraphy when lymphatic obstruction is present. 32 The false-negative rate for SLNB is not insignificant, with reports ranging from 1.5-21% depending on the method of calculation. 33, 34 Our false-negative rate was 10.4%, as calculated by the following formula: [false negative/(false negative ? true positive)] 9 100%. In addition to eight nodal recurrences mentioned previously, one patient who had a positive SLNB in the observation arm of the multicenter Selective Lymphadenectomy Trial II (MSLT-II) randomized trial also experienced a recurrence in the nodal basin after 16 months. Ultrasound may detect abnormal lymph nodes by morphologic criteria and therefore possibly reduce the false-negative SLNB rate. 8, 14, 19 However, ultrasound has its limitations: visualization varies depending on the anatomic location and the operator. Ultrasound is more difficult in the axilla than in the groin or neck, where the nodes are closer to the skin. 13 In our study, the highest sensitivity was observed in the neck (43.2%), then the axilla (34.1%) and groin (30%).
Another limitation of ultrasound is the threshold size for detection of tumor deposits. We did not include the tumor deposit size observed in positive lymph nodes in our analysis because no standard method of measuring the tumor deposit was used, but many of our patients had microscopic metastases measuring less than 1 mm. The threshold size of tumor deposit for ultrasound detection has been discussed in multiple studies. 13, 18, 25, 35 Starritt et al. showed that targeted ultrasound (performed after lymphoscintigraphy) of sentinel nodes can detect metastatic melanoma deposits as small as 4.5 mm in diameter. 13 Rossi et al. performed nontargeted preoperative ultrasound in 125 patients with melanoma of [1 mm thickness; ultrasound could not detect tumor deposits of \2 mm. 18 Van Akkooi et al. reported a lesion as small as 0.5 mm in maximum diameter in a lymph node as small as 6 9 6 mm could be detected by an ultrasound. 6 Voit et al. however, reported that ultrasound-guided FNA could detect sentinel node tumors[1 mm in 76%, 0.1 to 1 mm in 46%, and\0.1 mm in 23% of cases. 17 The significance of micrometastases \0.1 mm has been questioned; whether patients with a positive SLNB need a completion lymphadenectomy remains unclear. 36, 37 A better understanding of the significance of micrometastases will help investigators determine the appropriate deposit size that the ultrasound must detect. Table 3 compares the sensitivity, specificity, PPV, and NPV of preoperative ultrasound in previous studies and our own. Our study and those done by the groups of Rossi, Hocevar, van Rijk, and Sibon were performed without lymphoscintigraphy targeting of the draining nodal basin, whereas the studies by the groups of Voit and Sanki were performed after lymphoscintigraphy. 15, 16, 18, [38] [39] [40] It is difficult to compare these studies directly because targeting draining nodal basins may affect sensitivity and specificity. Furthermore, the patient and tumor characteristics also vary and can influence the results. Table 3 demonstrates a wide variability in the results of preoperative ultrasound.
The reported value of ultrasound-guided FNA also varies widely. The recent study by Voit et al. stated that in their institution up to 65% of patients with positive sentinel lymph nodes could avoid SLNB with a lymphoscintigraphy-targeted, ultrasound-guided FNA of suspicious nodes using their criteria. 17 But in the study by Hocevar et al., only three of 57 patients (5.2%) avoided SLNB and proceeded directly to one-stage surgery by ultrasoundguided FNA. 38 Rossi et al. and van Rijk et al. reported the number of patients who avoided SLNB by undergoing ultrasound-guided FNA to be 10 and 2%, respectively. 15, 18 Recently, Thompson et al. also reported their assessment of preoperative ultrasound efficacy for reliable staging in a large multicenter trial, the MSLT-II. In their study, positive sentinel nodes were characterized by either histopathologic or molecular evaluation. The sensitivity of ultrasound for detecting positive sentinel node in all lymph node fields was 8% (95% confidence interval 6-10.5%) and the specificity 97.3% (95% confidence interval 96.7-97.9%). The sentinel node with truly positive ultrasound results had a median cross-sectional area of 6.11 mm 2 , which is significantly greater than the median cross-sectional area of 0.16 mm 2 in sentinel nodes with falsely negative ultrasound results (P \ 0.001). The potential cost-effectiveness of ultrasound-guided FNA in melanoma has been researched by van Akkooi et al. 27 The cost analysis was made under the assumption that presurgical ultrasound-guided FNA cytology has a sensitivity of 65% compared with SLNB on the basis of the targeted ultrasound study by Voit et al. 17 For 100 patients with stage I/II melanoma, ultrasound-guided FNA (€56,115.2) offers a potential saving up to €69,367.80 (or $101,242.3) compared with SLNB (€125,483) as a staging procedure at their institution.
41
In our institution, use of axillary ultrasound for patients with CT2 breast cancer has been investigated. Ultrasound sensitivity was much higher at 86.2%, which is likely the result of inclusion of patients with palpable lymphadenopathy as well as less variation in lymphatic drainage pattern for breast cancer. Avoiding SLNB and proceeding to one-stage lymphadenectomy for breast cancer patients carried a savings of over $4000 (not including physician fees). 42 However, this result will unlikely translate directly to melanoma patients.
In fact, in our series, whether the abnormal lymph node seen on ultrasound is indeed the same node identified as a sentinel node is unclear. We had 40 abnormal ultrasounds in patients with negative SLNB, whereas 45 patients with positive nodal basins showed negative ultrasound. This raises a question about whether all 17 basins with positive sentinel nodes and abnormal ultrasounds really represented truly positive findings. Our study suggests that ultrasound is neither sensitive nor specific enough to detect melanoma sentinel node metastases without lymphoscintigraphy targeting. Because conventional rules such as Sappey's lines do not dependably predict drainage patterns of primary melanoma, lymphoscintigraphy allows identification of draining nodal basins, assuming no lymphatic obstruction is present. This could potentially increase the accuracybut also dramatically increase the cost-of ultrasound for detecting nodal metastases. 13, 34, 43, 44 Without preoperative lymphoscintigraphy, clinically targeted ultrasound may image nondraining nodal basins unnecessarily and miss draining basins that may harbor metastasis. Even correctly targeted basins are not reliably staged by preoperative ultrasound, although selective use in patients at high risk of nodal metastasis (e.g., those with thick, ulcerated tumors) may occasionally allow SLNB to be avoided. Ultrasound should continue to play a role in patients who chose not to have or are medically unfit for SLNB with the understanding of its low sensitivity. Although targeted ultrasound after lymphoscintigraphic localization may improve sensitivity and specificity, the cost-effectiveness and accuracy of ultrasound-guided FNA in small tumor deposits remain to be determined.
